Eko Health Expands into Canada with Launch of CORE 500™ Digital Stethoscope and Eko+ Membership

SAN FRANCISCO, Calif., April 9, 2025 – Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, today announced the launch of the CORE 500™ Digital Stethoscope and Eko+ membership in Canada. This expansion follows Health Canada approval of the CORE 500™ Digital Stethoscope and Eko+, making it available to Canadian clinicians seeking advanced digital auscultation technology to support cardiac and pulmonary care. With real-time visualization, AI-driven analysis, and seamless connectivity, Eko’s platform helps healthcare professionals make more informed assessments.

“Expanding into Canada is an exciting milestone for Eko as we continue to make high-quality digital stethoscopes and AI-powered solutions more accessible to clinicians worldwide,” said David Bakey, General Manager of Consumer at Eko Health. “With the launch of CORE 500™ and Eko+ in Canada, we’re empowering healthcare professionals with cutting-edge tools that enhance auscultation, support clinical decision-making, and ultimately help improve patient care. We’re excited to bring this technology to more providers and patients across Canada.”

The CORE 500™ Digital Stethoscope is Eko’s most advanced stethoscope to date, designed to enhance clinical assessments through patented audio technology with three listening modes (cardiac, pulmonary, and wide), simultaneous ECG and heart sound visualization, and active noise cancellation for clear auscultation in any environment. It seamlessly connects with Eko’s mobile and web applications for data capture, sharing, and patient monitoring. The CORE 500™ is available through Eko's website and includes a free trial membership to Eko+.

Eko+ is a subscription-based membership designed to enhance the capabilities of Eko’s digital stethoscopes. Now available in Canada through the Apple App Store and Google Play Store, Eko+ provides AI-supported heart murmur and AFib detection, tachycardia and bradycardia identification, real-time waveform visualization, guided multi-point exam flow, and secure recording and sharing for asynchronous consultations. 

Healthcare professionals across Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Ontario, Prince Edward Island, Saskatchewan, and Yukon can now order CORE 500™ and Eko+ through Eko’s website.

For more insights into Eko Health and its portfolio of transformative cardiopulmonary solutions, please visit www.ekohealth.com.

About Eko Health

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform, used by over 500,000 healthcare professionals worldwide, allows them to detect earlier and with higher accuracy, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $165 million in funding from ARTIS Ventures, DigiTx Partners, Double Point Ventures, EDBI, Highland Capital Partners, LG Technology Ventures, Mayo Clinic, Morningside Technology Ventures Limited, NTTVC, Questa Capital, and others.

Media contact

Sam Moore
sam.moore@ekohealth.com

MKT-0003630 Rev 1.0